Controversy Erupts as Novo Nordisk Faces Criticism Over Payments to Patients and Health Groups in the UK

In a recent development that has sparked significant debate, Novo Nordisk, one of the leading pharmaceutical companies, has come under fire in the UK for its financial relationships with patients and healthcare organizations. The criticisms reveal complex ethical questions surrounding the pharmaceutical industry’s impact on both patient care and public trust.

Continue reading